Future treatment options for Gram-positive infections - looking ahead

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL.6, 2009, Pages 17-25

  Barton, E ^a   MacGowan, A ^a  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

Bacteraemia; Gram positive infections; Staphylococcus aureus; Therapeutic options

Indexed keywords

ANTIBIOTIC AGENT; BAY 41 6551; CEFALEXIN; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CREATINE KINASE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FUSIDIC ACID; GEMIFLOXACIN; GLYCOPEPTIDE; ICLAPRIM; IMIPENEM; IMMUNOGLOBULIN; LINEZOLID; MOXIFLOXACIN; ORITAVANCIN; PLACEBO; PTK 0796; PZ 601; RADEZOLID; RETAPAMULIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; TOMOPENEM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ABSCESS; ACUTE PANCREATITIS; ACUTE SINUSITIS; ANEMIA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CATHETER INFECTION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DYSPEPSIA; EDEMA; ENTEROCOCCAL INFECTION; EOSINOPHIL; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNOTHERAPY; IMPETIGO; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LACTIC ACIDOSIS; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYALGIA; MYCOSIS; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL; OPTIC NERVE DISEASE; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THRUSH; TONGUE DISEASE; TOXIC SHOCK SYNDROME; VAGINA CANDIDIASIS; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 73249153681     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03055.x     Document Type: Review

References (75)

1. Provan D, Chapel HM, Sewell WA, O'Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 2008, 337:a1831.
2. Rupp ME, Holley HP, Lutz J. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in the treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007, 51:4249-4254.
3. Pitts K, Brown DFJ, Barnard A, Wilkinson A, Fairhead H. SASP: rapid bactericidal activity against MRSA and stationary phase Staphylococcus aureus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract F1-2131
4. Wilkinson A, Holmes S, Pitts K. SASP: a novel antibacterial DNA binding protein and its targeted delivery to Staphylococcus aureus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract F1-2132
5. Bowker KE, Noel AR, MacGowan AP, Pitts K, Wilkinson A, Fairhead H. SASP: kill kinetics against diverse antibiotic resistant Staphylococcus aureus. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract F1-2133
6. Sandvang D, Mygind PH, Jones ME, Sahm DF, Kristensen H. In vitro activity and characterization of NZ2114: an improved variant of plectasin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract F1-1663
7. Torres MK, Draghi DC, Brown NP. Activity of NZ2114 against staphylococcal and streptococcal isolates, including resistant phenotypes. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract F1-3962
8. Hillman JD, Novak J, Sagura E. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun 1998, 66:2743-2749.
9. Wootton M, Caetano T, Dempsey C, Hawrani A, Walsh TR, Howe RA. The activity of RTA-3, a novel antimicrobial peptide, against Staphylococcus aureus (SA) of various resistance phenotypes. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract F1-3999
10. Miller K, Ooi N, Rhys-Williams W, Love WG, Hayter I, Chopra I. XF-73, a new antimicrobial drug with rapid membrane activity. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract F1-3976
11. Altabax Prescribing Information 2007
12. Altargo Summary of Product Characteristics 2008
13. Koning S, van der Wouden JC, Chosidow O. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008, 158:1077-1082.
14. Oranje AP, Chosidow O, Sacchidanand S. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007, 215:331-340.
15. Free A, Roth E, Dalessandro M. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed 2006, 5:224-232.
16. Parish LC, Jorizzo JL, Breton JJ. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol 2006, 55:1003-1013.
17. Corkery K, Eldon M, Gribben D, Fink J, Eldon M, Niederman M. Evidence of high amikacin lung deposition in mechanically ventilated patients (MVP) with pneumonia and healthy subjects (HS) dosed using NKTR-061. American Thoracic Society International Conference May 16-21, 2008, Toronto, Canada, Poster 517
18. Dhand R, Sohal H. Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008, 5:9-18.
19. Press release: Pfizer withdraws its marketing authorisation application for Exulett (dalbavancin). London, 10th September 2008
20. Press release: Astellas withdraws its marketing authorisation application for Vibativ (telavancin). London, 24th October 2008
21. Avelox Summary of Product Characteristics 2007
22. Synercid Summary of Product Characteristics 2005
23. Zyvox Summary of Product Characteristics 2007
24. Cubicin Summary of Product Characteristics 2008
25. Tygacil Summary of Product Characteristics 2008
26. Avelox Prescribing Information 2007
27. Questions and Answers: Moxifloxacin 2008, London, European Medicines Agency
28. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008, 47:735-743.
29. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007, 28:632-645.
30. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 2004, 17:549-555.
31. Press release: Wyeth withdraws its application to extend the marketing authorisation for Tygacil. London, 24th April 2008
32. Revill P, Serradell N, Bolos J. Tomopenem. Drugs Future 2007, 32:37.
33. Arbeit RD, Roberts J, Forsythe A. Safety and efficacy of PTK 0796: results of the phase 2 study in complicated skin and skin structure infections following IV and oral step-down therapy. Boston, MA, 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract L-1515b
34. Bhavnani SM, Okusanya OO, Hammel JP. Population pharmacokinetic and Monte Carlo simulation analyses to support phase 2/3 PZ-601 (SMP-601) dosing strategies for complicated skin and skin structure infections. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract 40
35. File T, Bagheri F, Bush L. A phase 2 study comparing two doses of radezolid to linezolid in adults with uncomplicated skin and skin structure infections (uSSSI). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract L-1515c
36. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis 2007, 7:29.
37. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr Opin Pharmacol 2004, 4:471-478.
38. Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006, 50:4195-4197.
39. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activity of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007, 51:1268-1273.
40. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008, 62(suppl 2):ii65-ii74.
41. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
42. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005, 49:4210-4219.
43. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004, 53:669-674.
44. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002, 43:75-83.
45. Baum SE, Crawford SA, McElmeel ML, Whitney CG, Jorgensen JH. Comparative activities of the oxazolidinone AZD2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002, 46:3094-3095.
46. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004, 53:797-803.
47. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58:338-343.
48. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 2007, 45:2173-2179.
49. Bell JM, Fritsche TR, Jones RN, Turnidge JD. Activity of ceftobiprole (BPR) tested against Gram-positive and -negative pathogens in the Asia-Pacific region: report from the SENTRY antimicrobial surveillance program (2006). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract E-277
50. Ge Y, Biek D, Sahm DF, Talbot GH. In vitro activity of ceftaroline against a collection of recent Gram-positive and Gram-negative U.S. isolates. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract C2-863
51. Saravolatz LD, Pawlak J, Johnson L. In vitro activity of ceftaroline against CA-MRSA, VISA, VRSA and daptomycin-non-susceptible Staphylococcus aureus (DNSSA). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract C1-162
52. Sader HS, Fritsche TR, Islam K, Hawser S, Jones RN. Antimicrobial activity of iclaprim tested against recent S. aureus clinical isolates: results from the international study of iclaprim susceptility (ISIS). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract E-902
53. Sader HS, Jones RN, Rhomberg PR, Islam K, Hawser S, Fritsche TR. Comparative evaluation of iclaprim potency and bactericidal activity tested against enterococci: results from the international study of iclaprim susceptibility (ISIS). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract E-910
54. Draghi DC, Sahm DF, Arhin FF, Moeck G. Anti-enterococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against Gram-positive infections. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract E-1615
55. Draghi DC, Sahm DF, Arhin FF, Moeck G. Anti-staphylococcal activity profile of oritavancin, a potent lipoglycopeptide under development for use against Gram-positive infections. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract E-1616
56. Sahm DF, Arhin FF, Moeck G, Draghi DC. In vitro activity profile of oritavancin against resistant staphylococcal populations from a recent surveillance initiative. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract E-1617
57. Saravolatz LD, Pawlak J, Johnson L. In vitro activity of oritavancin against CA-MRSA, VISA and daptomycin-non-susceptible Staphylococcus aureus (DNSSA). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract C1-187
58. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004, 48:4665-4672.
59. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004, 64:913-936.
60. Schmitt-Hoffmann A, Nyman L, Roos B. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004, 48:2576-2580.
61. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003, 47:1318-1323.
62. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003, 51(suppl 2):ii17-ii25.
63. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008, 62:780-783.
64. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49:220-229.
65. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005, 49:195-201.
66. Riccobene T, Fang E, Thye D. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract A-1888
67. Brandt R, Warrington S, McBurney A, Islam K. Tolerability and pharmacokinetics of single and repeat ascending doses of iclaprim in healthy adults. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract A-804
68. Chien J, Allerheiligen S, Philips DL, Cerimele B, Thomasson HR. Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphonate (glycopeptide) in healthy men. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy September 24-27, 1998, San Diego, USA, Abstract A-55
69. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006, 58:256-265.
70. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008, 62(suppl 1):i11-i16.
71. Pertel PE, Bernardo P, Fogarty C. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008, 46:1142-1151.
72. Maroko R, Cooper A, Dukart G, Dartois N, Gandjini H. Results of phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy September 17-20, 2007, Chicago, USA, Abstract L-730
73. Zyvox Prescribing Information 2008
74. Noel GJ, Strauss RS, Shah A, Bagchi P. Ceftobiprole (BPR) versus ceftazidime (CAZ) combined with linezolid (LZD) for treatment of patients with nosocomial pneumonia (NP). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract K-486
75. Rubinstein E, Corey GR, Stryjewski ME. Telavancin for treatment of hospital-acquired pneumonia caused by MRSA and MSSA: The ATTAIN studies. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008, Washington, DC, USA, Abstract K-530